Triple agonist
What a GLP-1 receptor agonist actually does: which receptors it reaches, how it slows gastric emptying, and the satiety pathway it runs through.
What is Triple agonist?
A peptide activating three metabolic receptors at once, typically GIP, GLP-1 and glucagon.
Retatrutide is the first in clinical development for weight loss, with the glucagon arm hypothesized to add energy expenditure on top of appetite suppression. None is approved, which does not stop them being sold.
Related reading: Retatrutide: What the Evidence Actually Shows
GLP Watchdog writes these definitions from FDA labels and peer-reviewed PubMed literature.
Where Triple agonist comes up on this site
On GLP Watchdog, Triple agonist comes up in 1 research article and 2 FDA warning letters. Browse the FDA warning letters.
Research that discusses it
Connected terms
Other terms under Mechanism
- GLP-1 receptor
- GIP receptor
- Dual agonist
- Gastric emptying
- Food noise
- Amylin
- GLP-1 tachyphylaxis
- Non-peptide GLP-1 agonist
- A1C (glycated hemoglobin)
- MASH / MASLD
- TBWL (Total Body Weight Loss)
- C-peptide
- eGFR (estimated glomerular filtration rate)
- Visceral adipose tissue (VAT)
- AHI (apnea-hypopnea index)
- SNAC (oral semaglutide absorption enhancer)
Where the evidence lives
- The full GLP-1 glossary (150 terms, 8 categories)
- Research articles — written from primary sources
- Tools and calculators
- Compare GLP-1 telehealth providers